Aurenar has secured $5.7 million in seed funding to advance V-Link, an investigational, non-invasive neuromodulation device designed to help intensive care patients, according to company announcements. The wireless, single-use system delivers transauricular vagus nerve stimulation through the outer ear and recently earned FDA Breakthrough Device designation.
Funding Fuels V-Link Device Development and Clinical Trials
The newly acquired capital will allow Aurenar to complete device development, according to company disclosures. Engineers and researchers will conduct verification and validation testing, prepare regulatory submissions for the U.S. Food and Drug Administration, and advance the technology toward a pivotal clinical trial.
V-Link is initially being developed for adults suffering from aneurysmal subarachnoid hemorrhage. In these critical cases, the device’s stimulation is intended to help regulate inflammation and reduce cerebral vasospasm when used alongside standard clinical care.
Did you know?
Transauricular vagus nerve stimulation delivers electrical impulses to the auricular branch of the vagus nerve through the skin of the outer ear, bypassing the need for surgical implantation.
Addressing Critical Care Complications
For patients and clinicians managing severe brain hemorrhages, V-Link could add a vital non-invasive neuromodulation option. Intensive care units frequently handle complex secondary complications like cerebral vasospasm, where blood vessels in the brain narrow dangerously after a hemorrhage.
According to market analysis surrounding the financing round, the investment highlights a broader surge of capital into evidence-based neurotechnology. Investors are increasingly targeting platforms designed to improve patient outcomes specifically within acute and critical care environments.
Frequently Asked Questions
What is Aurenar’s V-Link device?
V-Link is an investigational, wireless, single-use neuromodulation device that delivers transauricular vagus nerve stimulation through the outer ear for intensive care patients.
What condition is V-Link initially targeting?
The device is being developed for adults with aneurysmal subarachnoid hemorrhage to help regulate inflammation and reduce cerebral vasospasm alongside standard care.
What regulatory milestone has the device achieved?
V-Link recently received FDA Breakthrough Device designation, a status intended to speed up the development and review of medical devices that offer more effective treatment for life-threatening conditions.
Want to stay updated on the latest breakthroughs in neurotechnology and critical care devices? Leave a comment below or subscribe to our newsletter for regular industry updates.
Related reading